Thijs Thomas Jansz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thijs Thomas Jansz has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Angus G. Jones
Department of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK
5 shared publications - Katherine G. Young
University of Exeter Medical School
5 shared publications - Andrew Peter McGovern
Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, UK, EX2 5GL
4 shared publications - Andrew Tym Hattersley
Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK
4 shared publications - Beverley M. Shields
Department of Clinical and Biomedical Sciences University of Exeter Medical School Exeter UK
4 shared publications - Ewan Robert Pearson
Population Health & Genomics, School of Medicine, University of Dundee, Dundee, UK
4 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (8)
Interpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy
- 12 August 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (8)
Open AccessInterpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy
- Open Access
- 20 May 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (6) , 1115-1123
Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study
OBJECTIVE: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce heart failure (HF) risk in type 2 diabetes (T2D) and are recommended for patients with T2D who have atherosclerotic cardiovascular disease (ASCVD), HF, or chronic kidney disease (CKD). However, most individuals with T2D do not have these conditions, and current guidelines for this group do not indicate which individuals may benefit most from SGLT2i. We aimed to develop and validate a model to predict the individual-level HF benefit of SGLT2i in individuals with T2D without ASCVD, HF, or CKD. RESEARCH DESIGN AND METHODS: We developed the SGLT2i Absolute Benefit Response (SABRE) model, combining absolute HF risk from the validated QDiabetes-HF model with the SGLT2i-associated hazard ratio (HR) for HF hospitalization from a trial meta-analysis (HR 0.63) to estimate individual 5-year HF benefit. Model components and predictions were validated using U.K. primary care data with linked hospital and death records from 2013 to 2020. RESULTS: Among 57,368 SGLT2i initiators and 111,673 comparator (dipeptidyl peptidase 4 inhibitor or sulfonylurea) initiators, SGLT2i use was associated with a 30% lower risk of new-onset HF (HR 0.70 [95% CI 0.63–0.78]), consistent with trial evidence. Relative HF benefit did not vary by baseline absolute HF risk (P = 0.82). The SABRE model–predicted 5-year absolute HF benefit with SGLT2i ranged from <0.1% to 14.1% (median 1.0% [interquartile range 0.6–1.8%]) and calibrated well against observed HF outcomes. SABRE provided more targeted HF prevention than current guidelines in those with T2D without ASCVD, HF, or CKD. CONCLUSIONS: The SABRE model is an easily deployed clinical prediction model integrating trial evidence and allowing more precise targeting of SGLT2i for primary HF prevention in T2D.
- 20 May 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (6) , 1115-1123
Open AccessPrecision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study
OBJECTIVE: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce heart failure (HF) risk in type 2 diabetes (T2D) and are recommended for patients with T2D who have atherosclerotic cardiovascular disease (ASCVD), HF, or chronic kidney disease (CKD). However, most individuals with T2D do not have these conditions, and current guidelines for this group do not indicate which individuals may benefit most from SGLT2i. We aimed to develop and validate a model to predict the individual-level HF benefit of SGLT2i in individuals with T2D without ASCVD, HF, or CKD. RESEARCH DESIGN AND METHODS: We developed the SGLT2i Absolute Benefit Response (SABRE) model, combining absolute HF risk from the validated QDiabetes-HF model with the SGLT2i-associated hazard ratio (HR) for HF hospitalization from a trial meta-analysis (HR 0.63) to estimate individual 5-year HF benefit. Model components and predictions were validated using U.K. primary care data with linked hospital and death records from 2013 to 2020. RESULTS: Among 57,368 SGLT2i initiators and 111,673 comparator (dipeptidyl peptidase 4 inhibitor or sulfonylurea) initiators, SGLT2i use was associated with a 30% lower risk of new-onset HF (HR 0.70 [95% CI 0.63–0.78]), consistent with trial evidence. Relative HF benefit did not vary by baseline absolute HF risk (P = 0.82). The SABRE model–predicted 5-year absolute HF benefit with SGLT2i ranged from <0.1% to 14.1% (median 1.0% [interquartile range 0.6–1.8%]) and calibrated well against observed HF outcomes. SABRE provided more targeted HF prevention than current guidelines in those with T2D without ASCVD, HF, or CKD. CONCLUSIONS: The SABRE model is an easily deployed clinical prediction model integrating trial evidence and allowing more precise targeting of SGLT2i for primary HF prevention in T2D.
- Open Access
- 16 April 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (4)
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data
- 16 April 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (4)
Open AccessKidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data
- Open Access
- 9 November 2025
- Published by Springer Nature in Diabetologia
- Vol. 69 (2) , 374-385
Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection
Aims/hypothesis: Current guidelines recommend use of sodium–glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. However, individuals with a normal uACR or low-level albuminuria were not represented in kidney outcome trials, leaving uncertainty about absolute treatment benefit in this group. To address this gap and support treatment decisions in clinical practice, we developed and validated a model to predict individual-level kidney protection benefit through the use of SGLT2 inhibitors. Methods: This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013–2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR n =25,303, 17.9%) as the albuminuria threshold would prevent over 10% more events over 3 years (253 vs 228) by identifying a subgroup of 6.7% of individuals with uACR p =0.05). Conclusions/interpretation: A model adapting the international CKD-PC risk score can accurately predict the individual-level kidney protection benefit from treatment with SGLT2 inhibitors in people with type 2 diabetes and no or early-stage CKD. This could guide treatment decisions in clinical practice worldwide and could target treatment more effectively than the ≥3 mg/mmol albuminuria threshold recommended by current international guidelines. Graphical
- 9 November 2025
- Published by Springer Nature in Diabetologia
- Vol. 69 (2) , 374-385
Open AccessPrecision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection
Aims/hypothesis: Current guidelines recommend use of sodium–glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. However, individuals with a normal uACR or low-level albuminuria were not represented in kidney outcome trials, leaving uncertainty about absolute treatment benefit in this group. To address this gap and support treatment decisions in clinical practice, we developed and validated a model to predict individual-level kidney protection benefit through the use of SGLT2 inhibitors. Methods: This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013–2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR n =25,303, 17.9%) as the albuminuria threshold would prevent over 10% more events over 3 years (253 vs 228) by identifying a subgroup of 6.7% of individuals with uACR p =0.05). Conclusions/interpretation: A model adapting the international CKD-PC risk score can accurately predict the individual-level kidney protection benefit from treatment with SGLT2 inhibitors in people with type 2 diabetes and no or early-stage CKD. This could guide treatment decisions in clinical practice worldwide and could target treatment more effectively than the ≥3 mg/mmol albuminuria threshold recommended by current international guidelines. Graphical
- Open Access
Precision prescribing of SGLT2-inhibitors in people with type 2 diabetes for primary prevention of heart failure: model development and validation study
Objectives To develop and validate a model to predict individual-level benefits of SGLT2-inhibitors for heart failure prevention in people with type 2 diabetes who do not have atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) or chronic kidney disease (CKD). Design Population based cohort study. Setting The SGLT2-inhibitor absolute response (SABRE) model estimated individual-level 5-year heart failure benefits using absolute heart failure risk predictions from the previously validated QDiabetes-Heart Failure model, combined with the hazard ratio of SGLT2i-associated hospitalisation for heart failure benefit (HR: 0.63 [95% CI: 0.50 to 0.80]) from trial meta-analysis. The data source was primary care records with linked hospital admission and death records (Clinical Practice Research Datalink, England) from January 2013 to October 2020. Population Adults with T2D without ASCVD, HF or CKD initiating an SGLT2i (n=57,368) or, as a comparator group, DPP4-inhibitors or sulfonylureas (n=111,673). Propensity score weighting and regression adjustment were used to mitigate potential treatment selection bias. Validation of model accuracy was performed by comparing the calibration of predicted versus observed heart failure benefits in those receiving SGLT2i versus comparator therapy. Main outcome measures New-onset heart failure recorded in primary care, linked hospital or death records. Results Amongst 57,368 SGLT2i and 111,673 DPP4i/SU treatment initiations, estimated risk of new-onset heart failure was 30% lower with SGLT2i versus the comparator arm (HR: 0.70 [95% CI: 0.63 to 0.78]), similar to trial meta-analysis for hospitalisation for heart failure. The relative benefit of SGLT2i on heart failure was consistent across all levels of baseline absolute heart failure risk as estimated from the QDiabetes-Heart Failure model (p=0.82 for treatment arm:baseline heart failure risk interaction). 5-year absolute heart failure benefit predictions with SGLT2i ranged from Conclusions SGLT2i can be targeted to individuals with type 2 diabetes without ASCVD/HF/CKD for primary prevention of heart failure using an easily deployed clinical prediction model integrating evidence from clinical trials.
Open AccessPrecision prescribing of SGLT2-inhibitors in people with type 2 diabetes for primary prevention of heart failure: model development and validation study
Objectives To develop and validate a model to predict individual-level benefits of SGLT2-inhibitors for heart failure prevention in people with type 2 diabetes who do not have atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) or chronic kidney disease (CKD). Design Population based cohort study. Setting The SGLT2-inhibitor absolute response (SABRE) model estimated individual-level 5-year heart failure benefits using absolute heart failure risk predictions from the previously validated QDiabetes-Heart Failure model, combined with the hazard ratio of SGLT2i-associated hospitalisation for heart failure benefit (HR: 0.63 [95% CI: 0.50 to 0.80]) from trial meta-analysis. The data source was primary care records with linked hospital admission and death records (Clinical Practice Research Datalink, England) from January 2013 to October 2020. Population Adults with T2D without ASCVD, HF or CKD initiating an SGLT2i (n=57,368) or, as a comparator group, DPP4-inhibitors or sulfonylureas (n=111,673). Propensity score weighting and regression adjustment were used to mitigate potential treatment selection bias. Validation of model accuracy was performed by comparing the calibration of predicted versus observed heart failure benefits in those receiving SGLT2i versus comparator therapy. Main outcome measures New-onset heart failure recorded in primary care, linked hospital or death records. Results Amongst 57,368 SGLT2i and 111,673 DPP4i/SU treatment initiations, estimated risk of new-onset heart failure was 30% lower with SGLT2i versus the comparator arm (HR: 0.70 [95% CI: 0.63 to 0.78]), similar to trial meta-analysis for hospitalisation for heart failure. The relative benefit of SGLT2i on heart failure was consistent across all levels of baseline absolute heart failure risk as estimated from the QDiabetes-Heart Failure model (p=0.82 for treatment arm:baseline heart failure risk interaction). 5-year absolute heart failure benefit predictions with SGLT2i ranged from Conclusions SGLT2i can be targeted to individuals with type 2 diabetes without ASCVD/HF/CKD for primary prevention of heart failure using an easily deployed clinical prediction model integrating evidence from clinical trials.
- Open Access
Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection
Aims/hypothesis: Current guidelines recommend use of sodium–glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. However, individuals with a normal uACR or low-level albuminuria were not represented in kidney outcome trials, leaving uncertainty about absolute treatment benefit in this group. To address this gap and support treatment decisions in clinical practice, we developed and validated a model to predict individual-level kidney protection benefit through use of SGLT2 inhibitors. Methods: This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013–2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR n =25,303, 17.9%) as the albuminuria threshold would prevent over 10% more events over 3 years (253 vs 228) by identifying a subgroup of 6.7% of individuals with uACR p =0.05). Conclusions/interpretation: A model adapting the international CKD-PC risk score can accurately predict the individual-level kidney protection benefit from treatment with SGLT2 inhibitors in people with type 2 diabetes and no or early-stage CKD. This could guide treatment decisions in clinical practice worldwide. and could target treatment more effectively than the ≥3 mg/mmol albuminuria threshold recommended by current international guidelines. Research in context: What is already known about this subject?: Sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce the risk of kidney failure in people with type 2 diabetes Current guidelines recommend use of SGLT2 inhibitors for kidney protection in individuals with type 2 diabetes and urinary albumin/creatinine ratio ≥3 mg/mmol, but this is an extrapolation beyond current evidence from kidney outcome trials It is unclear which people with type 2 diabetes and preserved eGFR and a normal urinary albumin/creatinine ratio or low-level albuminuria have clinically relevant kidney protection benefit from SGLT2 inhibitors What is the key question?: Can a model integrating an established risk score with the relative treatment effect from a SGLT2 inhibitor trial meta-analysis accurately predict individual-level kidney protection benefit? What are the new findings?: The model accurately predicted individual-level kidney protection benefit with SGLT2 inhibitor treatment in an external validation using UK primary care data Compared with the ≥3 mg/mmol albuminuria threshold, the model more effectively identified individuals who are likely to benefit, and could prevent more adverse kidney events How might this impact on clinical practice in the foreseeable future?: The model enables individualised prescribing of SGLT2 inhibitors for kidney protection, which could optimise treatment allocation and improve kidney outcomes
Open AccessPrecision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection
Aims/hypothesis: Current guidelines recommend use of sodium–glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. However, individuals with a normal uACR or low-level albuminuria were not represented in kidney outcome trials, leaving uncertainty about absolute treatment benefit in this group. To address this gap and support treatment decisions in clinical practice, we developed and validated a model to predict individual-level kidney protection benefit through use of SGLT2 inhibitors. Methods: This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013–2020) of adults with type 2 diabetes, eGFR ≥60 ml/min per 1.73 m 2 and uACR n =25,303, 17.9%) as the albuminuria threshold would prevent over 10% more events over 3 years (253 vs 228) by identifying a subgroup of 6.7% of individuals with uACR p =0.05). Conclusions/interpretation: A model adapting the international CKD-PC risk score can accurately predict the individual-level kidney protection benefit from treatment with SGLT2 inhibitors in people with type 2 diabetes and no or early-stage CKD. This could guide treatment decisions in clinical practice worldwide. and could target treatment more effectively than the ≥3 mg/mmol albuminuria threshold recommended by current international guidelines. Research in context: What is already known about this subject?: Sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce the risk of kidney failure in people with type 2 diabetes Current guidelines recommend use of SGLT2 inhibitors for kidney protection in individuals with type 2 diabetes and urinary albumin/creatinine ratio ≥3 mg/mmol, but this is an extrapolation beyond current evidence from kidney outcome trials It is unclear which people with type 2 diabetes and preserved eGFR and a normal urinary albumin/creatinine ratio or low-level albuminuria have clinically relevant kidney protection benefit from SGLT2 inhibitors What is the key question?: Can a model integrating an established risk score with the relative treatment effect from a SGLT2 inhibitor trial meta-analysis accurately predict individual-level kidney protection benefit? What are the new findings?: The model accurately predicted individual-level kidney protection benefit with SGLT2 inhibitor treatment in an external validation using UK primary care data Compared with the ≥3 mg/mmol albuminuria threshold, the model more effectively identified individuals who are likely to benefit, and could prevent more adverse kidney events How might this impact on clinical practice in the foreseeable future?: The model enables individualised prescribing of SGLT2 inhibitors for kidney protection, which could optimise treatment allocation and improve kidney outcomes
- Open Access
- 30 December 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12) , e0244639
Progression of coronary artery calcification in conventional hemodialysis, nocturnal hemodialysis, and kidney transplantation
Introduction: Cardiovascular disease is the leading cause of death in end-stage renal disease (ESRD) and is strongly associated with vascular calcification. An important driver of vascular calcification is high phosphate levels, but these become lower when patients initiate nocturnal hemodialysis or receive a kidney transplant. However, it is unknown whether nocturnal hemodialysis or kidney transplantation mitigate vascular calcification. Therefore, we compared progression of coronary artery calcification (CAC) between patients treated with conventional hemodialysis, nocturnal hemodialysis, and kidney transplant recipients.Methods: We measured CAC annually up to 3 years in 114 patients with ESRD that were transplantation candidates: 32 that continued conventional hemodialysis, 34 that initiated nocturnal hemodialysis (≥4x 8 hours/week), and 48 that received a kidney transplant. We compared CAC progression between groups as the difference in square root transformed volume scores per year (ΔCAC SQRV) using linear mixed models. Reference category was conventional hemodialysis.Results: The mean age of the study population was 53 ±13 years, 75 (66%) were male, and median dialysis duration was 28 (IQR 12–56) months. Median CAC score at enrollment was 171 (IQR 10–647), which did not differ significantly between treatment groups (P = 0.83). Compared to conventional hemodialysis, CAC progression was non-significantly different in nocturnal hemodialysis -0.10 (95% CI -0.77 to 0.57) and kidney transplantation -0.33 (95% CI -0.96 to 0.29) in adjusted models.Conclusions: Nocturnal hemodialysis and kidney transplantation are not associated with significantly less CAC progression compared to conventional hemodialysis during up to 3 years follow-up. Further studies are needed to confirm these findings, to determine which type of calcification is measured with CAC in end-stage renal disease, and whether that reflects cardiovascular risk.
- 30 December 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12) , e0244639
Open AccessProgression of coronary artery calcification in conventional hemodialysis, nocturnal hemodialysis, and kidney transplantation
Introduction: Cardiovascular disease is the leading cause of death in end-stage renal disease (ESRD) and is strongly associated with vascular calcification. An important driver of vascular calcification is high phosphate levels, but these become lower when patients initiate nocturnal hemodialysis or receive a kidney transplant. However, it is unknown whether nocturnal hemodialysis or kidney transplantation mitigate vascular calcification. Therefore, we compared progression of coronary artery calcification (CAC) between patients treated with conventional hemodialysis, nocturnal hemodialysis, and kidney transplant recipients.Methods: We measured CAC annually up to 3 years in 114 patients with ESRD that were transplantation candidates: 32 that continued conventional hemodialysis, 34 that initiated nocturnal hemodialysis (≥4x 8 hours/week), and 48 that received a kidney transplant. We compared CAC progression between groups as the difference in square root transformed volume scores per year (ΔCAC SQRV) using linear mixed models. Reference category was conventional hemodialysis.Results: The mean age of the study population was 53 ±13 years, 75 (66%) were male, and median dialysis duration was 28 (IQR 12–56) months. Median CAC score at enrollment was 171 (IQR 10–647), which did not differ significantly between treatment groups (P = 0.83). Compared to conventional hemodialysis, CAC progression was non-significantly different in nocturnal hemodialysis -0.10 (95% CI -0.77 to 0.57) and kidney transplantation -0.33 (95% CI -0.96 to 0.29) in adjusted models.Conclusions: Nocturnal hemodialysis and kidney transplantation are not associated with significantly less CAC progression compared to conventional hemodialysis during up to 3 years follow-up. Further studies are needed to confirm these findings, to determine which type of calcification is measured with CAC in end-stage renal disease, and whether that reflects cardiovascular risk.
- Open Access
- 18 November 2019
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (3) , 488-495
Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry
Background: Previous US studies have indicated that haemodialysis with ≥6-h sessions [extended-hours haemodialysis (EHD)] may improve patient survival. However, patient characteristics and treatment practices vary between the USA and Europe. We therefore investigated the effect of EHD three times weekly on survival compared with conventional haemodialysis (CHD) among European patients. Methods: We included patients who were treated with haemodialysis between 2010 and 2017 from eight countries providing data to the European Renal Association–European Dialysis and Transplant Association Registry. Haemodialysis session duration and frequency were recorded once every year or at every change of haemodialysis prescription and were categorized into three groups: CHD (three times weekly, 3.5–4 h/treatment), EHD (three times weekly, ≥6 h/treatment) or other. In the primary analyses we attributed death to the treatment at the time of death and in secondary analyses to EHD if ever initiated. We compared mortality risk for EHD to CHD with causal inference from marginal structural models, using Cox proportional hazards models weighted for the inverse probability of treatment and censoring and adjusted for potential confounders. Results: From a total of 142 460 patients, 1338 patients were ever treated with EHD (three times, 7.1 ± 0.8 h/week) and 89 819 patients were treated exclusively with CHD (three times, 3.9 ± 0.2 h/week). Crude mortality rates were 6.0 and 13.5/100 person-years. In the primary analyses, patients treated with EHD had an adjusted hazard ratio (HR) of 0.73 [95% confidence interval (CI) 0.62–0.85] compared with patients treated with CHD. When we attributed all deaths to EHD after initiation, the HR for EHD was comparable to the primary analyses [HR 0.80 (95% CI 0.71–0.90)]. Conclusions: EHD is associated with better survival in European patients treated with haemodialysis three times weekly.
- 18 November 2019
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (3) , 488-495
Open AccessSurvival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry
Background: Previous US studies have indicated that haemodialysis with ≥6-h sessions [extended-hours haemodialysis (EHD)] may improve patient survival. However, patient characteristics and treatment practices vary between the USA and Europe. We therefore investigated the effect of EHD three times weekly on survival compared with conventional haemodialysis (CHD) among European patients. Methods: We included patients who were treated with haemodialysis between 2010 and 2017 from eight countries providing data to the European Renal Association–European Dialysis and Transplant Association Registry. Haemodialysis session duration and frequency were recorded once every year or at every change of haemodialysis prescription and were categorized into three groups: CHD (three times weekly, 3.5–4 h/treatment), EHD (three times weekly, ≥6 h/treatment) or other. In the primary analyses we attributed death to the treatment at the time of death and in secondary analyses to EHD if ever initiated. We compared mortality risk for EHD to CHD with causal inference from marginal structural models, using Cox proportional hazards models weighted for the inverse probability of treatment and censoring and adjusted for potential confounders. Results: From a total of 142 460 patients, 1338 patients were ever treated with EHD (three times, 7.1 ± 0.8 h/week) and 89 819 patients were treated exclusively with CHD (three times, 3.9 ± 0.2 h/week). Crude mortality rates were 6.0 and 13.5/100 person-years. In the primary analyses, patients treated with EHD had an adjusted hazard ratio (HR) of 0.73 [95% confidence interval (CI) 0.62–0.85] compared with patients treated with CHD. When we attributed all deaths to EHD after initiation, the HR for EHD was comparable to the primary analyses [HR 0.80 (95% CI 0.71–0.90)]. Conclusions: EHD is associated with better survival in European patients treated with haemodialysis three times weekly.
- Open Access
- 14 November 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 31 (3) , 515-524
The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone
Summary The risk of vertebral fracture is unclear in end-stage renal disease. We report a high vertebral fracture prevalence and incidence in transplantation-eligible patients on dialysis, suggesting that these patients may benefit from radiographic screening for vertebral fractures. Parathyroid hormone had a U-shaped association with vertebral fracture risk. Introduction Vertebral fractures are often overlooked, but even undiagnosed vertebral fractures negatively impact physical functioning, quality of life, and mortality. The risk of vertebral fractures in end-stage renal disease (ESRD) patients is unclear, and parathyroid hormone (PTH) might play a role in the development of vertebral fractures. We therefore determined vertebral fracture prevalence and incidence in ESRD patients and assessed associations of vertebral trabecular bone mineral density (BMD) and PTH with vertebral fracture. Methods In 146 transplantation-eligible patients on dialysis, we determined vertebral fractures on lateral chest radiographs, which image the thoracic and upper lumbar spine. We determined incident vertebral fractures in 70 patients with follow-up radiographs (23 received a kidney transplant) after median 1.8 years. Vertebral trabecular BMD was measured with computed tomography, and PTH measured with 2-site immunoassays, categorized in tertiles with the middle tertile as reference. We used Poisson regression to assess associations of vertebral trabecular BMD and PTH with vertebral fracture. Results Mean age of the study population was 52 ± 13 years, and 98 (67%) were male. Median dialysis duration was 26 (IQR 13–55) months. Vertebral fractures were present in 50/146 patients (34%) and incident vertebral fractures occurred in 20/70 patients (29%). Vertebral trabecular BMD was not associated with vertebral fracture prevalence (relative risk 0.97, 95% CI 0.89 to 1.04). For the lowest PTH tertile (< 11 pmol/L), the relative risk of vertebral fracture was greater although not significant (2.28, 95% CI 0.97 to 5.97) and was significantly greater for the highest PTH tertile (≥ 30 pmol/L; 2.82, 95% CI 1.22 to 7.27) after adjustment for potential confounders. Conclusions The prevalence and incidence of vertebral fractures is high even in relatively young and healthy ESRD patients. Vertebral trabecular BMD is not associated with vertebral fracture, and the association of PTH with vertebral fracture risk appears U-shaped. Nevertheless, our study did not measure vertebral BMD using DXA and assessed vertebral fractures using lateral chest radiographs and not spine radiographs.
- 14 November 2019
- Published by Springer Nature in Osteoporosis International
- Vol. 31 (3) , 515-524
Open AccessThe prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone
Summary The risk of vertebral fracture is unclear in end-stage renal disease. We report a high vertebral fracture prevalence and incidence in transplantation-eligible patients on dialysis, suggesting that these patients may benefit from radiographic screening for vertebral fractures. Parathyroid hormone had a U-shaped association with vertebral fracture risk. Introduction Vertebral fractures are often overlooked, but even undiagnosed vertebral fractures negatively impact physical functioning, quality of life, and mortality. The risk of vertebral fractures in end-stage renal disease (ESRD) patients is unclear, and parathyroid hormone (PTH) might play a role in the development of vertebral fractures. We therefore determined vertebral fracture prevalence and incidence in ESRD patients and assessed associations of vertebral trabecular bone mineral density (BMD) and PTH with vertebral fracture. Methods In 146 transplantation-eligible patients on dialysis, we determined vertebral fractures on lateral chest radiographs, which image the thoracic and upper lumbar spine. We determined incident vertebral fractures in 70 patients with follow-up radiographs (23 received a kidney transplant) after median 1.8 years. Vertebral trabecular BMD was measured with computed tomography, and PTH measured with 2-site immunoassays, categorized in tertiles with the middle tertile as reference. We used Poisson regression to assess associations of vertebral trabecular BMD and PTH with vertebral fracture. Results Mean age of the study population was 52 ± 13 years, and 98 (67%) were male. Median dialysis duration was 26 (IQR 13–55) months. Vertebral fractures were present in 50/146 patients (34%) and incident vertebral fractures occurred in 20/70 patients (29%). Vertebral trabecular BMD was not associated with vertebral fracture prevalence (relative risk 0.97, 95% CI 0.89 to 1.04). For the lowest PTH tertile (< 11 pmol/L), the relative risk of vertebral fracture was greater although not significant (2.28, 95% CI 0.97 to 5.97) and was significantly greater for the highest PTH tertile (≥ 30 pmol/L; 2.82, 95% CI 1.22 to 7.27) after adjustment for potential confounders. Conclusions The prevalence and incidence of vertebral fractures is high even in relatively young and healthy ESRD patients. Vertebral trabecular BMD is not associated with vertebral fracture, and the association of PTH with vertebral fracture risk appears U-shaped. Nevertheless, our study did not measure vertebral BMD using DXA and assessed vertebral fractures using lateral chest radiographs and not spine radiographs.
- Open Access
- 13 November 2018
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 48 (5) , 369-377
Coronary Artery Calcification in Hemodialysis and Peritoneal Dialysis
Background: Vascular calcification is seen in most patients on dialysis and is strongly associated with cardiovascular mortality. Vascular calcification is promoted by phosphate, which generally reaches higher levels in hemodialysis than in peritoneal dialysis. However, whether vascular calcification develops less in peritoneal dialysis than in hemodialysis is currently unknown. Therefore, we compared coronary artery calcification (CAC), its progression, and calcification biomarkers between patients on hemodialysis and peritoneal dialysis. Methods: We measured CAC in 134 patients who had been treated exclusively with hemodialysis (n = 94) or peritoneal dialysis (n = 40) and were transplantation candidates. In 57 of them (34 on hemodialysis and 23 on peritoneal dialysis), we also measured CAC progression annually up to 3 years and the inactive species of desphospho-uncarboxylated matrix Gla protein (dp-ucMGP), fetuin-A, osteoprotegerin. We compared CAC cross-sectionally with Tobit regression. CAC progression was compared in 2 ways: with linear mixed models as the difference in square root transformed volume score per year (ΔCAC SQRV) and with Tobit mixed models. We adjusted for potential confounders. Results: In the cross-sectional cohort, CAC volume scores were 92 mm3 in hemodialysis and 492 mm3 in peritoneal dialysis (adjusted difference 436 mm3; 95% CI –47 to 919; p = 0.08). In the longitudinal cohort, peritoneal dialysis was associated with significantly more CAC progression defined as ΔCAC SQRV (adjusted difference 1.20; 95% CI 0.09 to 2.31; p = 0.03), but not with Tobit mixed models (adjusted difference in CAC score increase per year 106 mm3; 95% CI –140 to 352; p = 0.40). Peritoneal dialysis was associated with higher osteoprotegerin (adjusted p = 0.02) but not with dp-ucMGP or fetuin-A. Conclusions: Peritoneal dialysis is not associated with less CAC or CAC progression than hemodialysis, and perhaps with even more progression. This indicates that vascular calcification does not develop less in peritoneal dialysis than in hemodialysis.
- 13 November 2018
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 48 (5) , 369-377
Open AccessCoronary Artery Calcification in Hemodialysis and Peritoneal Dialysis
Background: Vascular calcification is seen in most patients on dialysis and is strongly associated with cardiovascular mortality. Vascular calcification is promoted by phosphate, which generally reaches higher levels in hemodialysis than in peritoneal dialysis. However, whether vascular calcification develops less in peritoneal dialysis than in hemodialysis is currently unknown. Therefore, we compared coronary artery calcification (CAC), its progression, and calcification biomarkers between patients on hemodialysis and peritoneal dialysis. Methods: We measured CAC in 134 patients who had been treated exclusively with hemodialysis (n = 94) or peritoneal dialysis (n = 40) and were transplantation candidates. In 57 of them (34 on hemodialysis and 23 on peritoneal dialysis), we also measured CAC progression annually up to 3 years and the inactive species of desphospho-uncarboxylated matrix Gla protein (dp-ucMGP), fetuin-A, osteoprotegerin. We compared CAC cross-sectionally with Tobit regression. CAC progression was compared in 2 ways: with linear mixed models as the difference in square root transformed volume score per year (ΔCAC SQRV) and with Tobit mixed models. We adjusted for potential confounders. Results: In the cross-sectional cohort, CAC volume scores were 92 mm3 in hemodialysis and 492 mm3 in peritoneal dialysis (adjusted difference 436 mm3; 95% CI –47 to 919; p = 0.08). In the longitudinal cohort, peritoneal dialysis was associated with significantly more CAC progression defined as ΔCAC SQRV (adjusted difference 1.20; 95% CI 0.09 to 2.31; p = 0.03), but not with Tobit mixed models (adjusted difference in CAC score increase per year 106 mm3; 95% CI –140 to 352; p = 0.40). Peritoneal dialysis was associated with higher osteoprotegerin (adjusted p = 0.02) but not with dp-ucMGP or fetuin-A. Conclusions: Peritoneal dialysis is not associated with less CAC or CAC progression than hemodialysis, and perhaps with even more progression. This indicates that vascular calcification does not develop less in peritoneal dialysis than in hemodialysis.